GenMark Diagnostics, Inc. (NASDAQ:GNMK) CFO Scott Mendel sold 2,879 shares of GenMark Diagnostics stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $4.74, for a total transaction of $13,646.46. Following the completion of the transaction, the chief financial officer now directly owns 133,114 shares in the company, valued at approximately $630,960.36. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Scott Mendel also recently made the following trade(s):

  • On Tuesday, November 14th, Scott Mendel sold 1,777 shares of GenMark Diagnostics stock. The stock was sold at an average price of $4.71, for a total transaction of $8,369.67.
  • On Thursday, November 2nd, Scott Mendel sold 326 shares of GenMark Diagnostics stock. The stock was sold at an average price of $7.24, for a total transaction of $2,360.24.

Shares of GenMark Diagnostics, Inc. (NASDAQ GNMK) traded down $0.07 on Friday, hitting $4.64. 334,300 shares of the company’s stock traded hands, compared to its average volume of 423,431. GenMark Diagnostics, Inc. has a one year low of $3.63 and a one year high of $13.67. The company has a quick ratio of 2.77, a current ratio of 2.97 and a debt-to-equity ratio of 0.12.

GenMark Diagnostics (NASDAQ:GNMK) last announced its earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.02). GenMark Diagnostics had a negative return on equity of 100.33% and a negative net margin of 116.76%. The firm had revenue of $11.60 million during the quarter, compared to analyst estimates of $14.56 million. During the same quarter in the previous year, the business earned ($0.27) earnings per share. The business’s quarterly revenue was up 7.4% compared to the same quarter last year. analysts anticipate that GenMark Diagnostics, Inc. will post -1.17 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first published by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.watchlistnews.com/genmark-diagnostics-inc-gnmk-cfo-sells-13646-46-in-stock/1724508.html.

GNMK has been the topic of several recent research reports. Canaccord Genuity reaffirmed a “buy” rating and issued a $14.00 price objective on shares of GenMark Diagnostics in a research note on Monday, October 30th. Cowen Inc reaffirmed a “buy” rating and issued a $10.00 price objective on shares of GenMark Diagnostics in a research note on Friday, November 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 price objective on shares of GenMark Diagnostics in a research note on Thursday, October 19th. Zacks Investment Research cut shares of GenMark Diagnostics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. Finally, Raymond James Financial, Inc. reaffirmed a “market perform” rating on shares of GenMark Diagnostics in a research note on Friday, November 3rd. Two research analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $11.80.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Legal & General Group Plc boosted its holdings in shares of GenMark Diagnostics by 2.1% in the second quarter. Legal & General Group Plc now owns 11,521 shares of the medical equipment provider’s stock worth $137,000 after buying an additional 240 shares during the period. Rhumbline Advisers boosted its holdings in shares of GenMark Diagnostics by 0.8% during the second quarter. Rhumbline Advisers now owns 48,445 shares of the medical equipment provider’s stock worth $573,000 after purchasing an additional 408 shares during the period. TIAA CREF Investment Management LLC boosted its holdings in shares of GenMark Diagnostics by 0.8% during the second quarter. TIAA CREF Investment Management LLC now owns 168,888 shares of the medical equipment provider’s stock worth $1,998,000 after purchasing an additional 1,268 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of GenMark Diagnostics by 4.1% during the second quarter. The Manufacturers Life Insurance Company now owns 36,023 shares of the medical equipment provider’s stock worth $426,000 after purchasing an additional 1,410 shares during the period. Finally, Quantitative Systematic Strategies LLC boosted its holdings in shares of GenMark Diagnostics by 18.4% during the second quarter. Quantitative Systematic Strategies LLC now owns 13,147 shares of the medical equipment provider’s stock worth $159,000 after purchasing an additional 2,047 shares during the period.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.